Neuphoria Therapeutics price target raised to $21 from $8 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Neuphoria Therapeutics (NEUP) to $21 from $8 and keeps a Buy rating on the shares. The firm believes the valuation argument for Neuphoria “is a compelling one” as the BNC210 “evolution pushes forward.”